Prostatic Diseases: Clinical Trials

155 trials for Prostatic Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

155 unknown. 155 Phase 2, 32 Phase 1, 12 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2155Unknown 155
Phase 132Unknown 32
Phase 312Unknown 12

Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases

Trials (filtered) newest first · largest first

All 155 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy
Receive Abiraterone plus prednisone/Enzalutamide/Apalutamide/Rezvilutamide in the evening - Prostate Cancer
Phase 2UnknownSun Yat-sen University702024-08-012024-08-05
Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage
Enzalutamide 40 MG, Docetaxel injection - Prostate Cancer, Castrate Resistant Prostate Cancer
Phase 2 / Phase 3UnknownZhongnan Hospital1202024-06-012024-02-28
To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
Zoladex, LY01005 - Prostate Cancer
Phase 2UnknownThe First Affiliated Hospital of Xiamen University602024-05-012024-04-26
Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer
Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment - Metastatic Hormone-Sensitive Prostate Cancer
Phase 2UnknownJianbin Bi1602023-11-152023-11-18
A Phase II Neoadjuvant Study of Darolutamide Plus ADT in Men With Localized Prostate Cancer
Darolutamide+ADT - Prostate Cancer
Phase 2UnknownPeking University First Hospital532023-08-052023-12-12
A Phase 2 Trial of Darolutamide as a Prostate-Specific Membrane Antigen (PSMA) Expression Enhancer in Patients With Localized Prostate Cancer
Darolutamide Oral Tablet [Nubeqa] - Prostate Cancer
Phase 2UnknownD'Or Institute for Research and Education192023-07-202023-08-07
Tracer-Guided Surgery for Recurrent Prostate Cancer
PSMA-radioguided surgery, ADT - Prostate Cancer
Phase 2UnknownThe Netherlands Cancer Institute602023-02-152023-10-06
[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2
[177Lu]Ludotadipep - Metastatic Castration-resistant Prostate Cancer, mCRPC
Phase 2UnknownFutureChem202022-10-302024-04-29
Early Salvage Stereotactic Radiotherapy for Biochemical Failure After RP
salvage SBRT - Prostatic Neoplasm
Phase 2UnknownRegina Elena Cancer Institute1032022-09-272022-12-28
EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC
177Lu-PSMA-617, Ipilimumab, Nivolumab - Prostatic Neoplasms, Genital Neoplasms, Male
Phase 2UnknownAustralian and New Zealand Urogenital and Prostate Cancer Trials Group932022-04-292023-12-15
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Leuprolide acetate, Goserelin acetate, Triptorelin acetate - Prostate Cancer
Phase 2UnknownFudan University1602022-04-012022-03-16
64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate Cancer
64Cu-SAR-bisPSMA - Prostate Cancer
Phase 1 / Phase 2UnknownLuke Nordquist, MD1502022-03-282022-03-18
The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation
Olaparib tablet, Abiraterone acetate, Prednisone tablet - Prostate Cancer, Prostate Carcinoma
Phase 2UnknownHongqian Guo302022-03-012022-10-25
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone - Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination
Phase 2UnknownWest China Hospital302022-01-012021-12-14
Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer
Darolutamide 300 mg, Androgen deprivation therapy - Prostate Cancer
Phase 2UnknownThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School302022-01-012023-01-03
The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation
Olaparib - Prostate Cancer, Prostate Carcinoma
Phase 2UnknownSun Yat-Sen Memorial Hospital of Sun Yat-Sen University302021-12-072022-03-02
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
Exercise - Exercise, Prostate Cancer
Phase 1 / Phase 2UnknownKira Murphy242021-09-092021-12-14
Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital
Cotrimoxazole, Placebo - Prostate Cancer, Prostate Biopsy
Phase 2UnknownUniversitas Indonesia782021-07-062021-08-05
Al18F-PSMA-617 and 68Ga-PSMA-617 PET/CT Imaging in the Same Group of Prostate Cancer Patients
Al18F-PSMA-617, 68Ga-PSMA-617 - Prostate Cancer
Phase 2 / Phase 3UnknownPeking Union Medical College Hospital1002021-07-012023-05-03
The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer
Metformin - Metastatic Prostate Cancer
Phase 2UnknownSun Yat-sen University2342021-06-232021-06-14

Showing 20 of 155. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (148)  ·  Neoplasms (8)  ·  Carcinoma, Non-Small-Cell Lung (6)  ·  Breast Neoplasms (5)  ·  Neoplasm Metastasis (5)  ·  Prostatic Hyperplasia (5)  ·  Stomach Neoplasms (4)  ·  Genital Neoplasms, Male (3)  ·  Neoplasms by Site (3)  ·  Pain (3)  ·  Pancreatic Neoplasms (3)  ·  Urogenital Neoplasms (3)  ·  Adenoviridae Infections (2)  ·  Carcinoma, Renal Cell (2)

Broader conditions

Genital Diseases (155)  ·  Male Urogenital Diseases (155)  ·  Urogenital Diseases (155)  ·  Genital Diseases, Male (154)  ·  Genital Neoplasms, Male (147)  ·  Neoplasms by Site (147)  ·  Urogenital Neoplasms (147)  ·  Neoplasms (142)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Pathologic Processes (11)  ·  Female Urogenital Diseases (8)  ·  Female Urogenital Diseases and Pregnancy Complications (8)  ·  Lung Diseases (7)  ·  Neoplastic Processes (7)

Interventions

Docetaxel (15)  ·  Abiraterone Acetate (11)  ·  Radiosurgery (9)  ·  Prednisone (8)  ·  Radiotherapy (8)  ·  enzalutamide (8)  ·  Goserelin (7)  ·  Androgen Antagonists (5)  ·  Leuprolide (4)  ·  abiraterone (4)  ·  acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide (4)  ·  apalutamide (4)  ·  cabazitaxel (4)  ·  Estramustine (3)  ·  Gonadotropin-Releasing Hormone (3)

Sponsors

Sunnybrook Health Sciences Centre (5)  ·  Fudan University (3)  ·  University College London Hospitals (3)  ·  West China Hospital (3)  ·  CyberKnife Centers of San Diego (2)  ·  Department of Veterans Affairs, New Jersey (2)  ·  Juravinski Cancer Center (2)  ·  Mansoura University (2)  ·  Novacea (2)  ·  Peking Union Medical College Hospital (2)  ·  Radboud University Medical Center (2)  ·  Roll International Corporation (2)  ·  Royal Marsden NHS Foundation Trust (2)  ·  Spanish Oncology Genito-Urinary Group (2)  ·  Sun Yat-sen University (2)

Countries

United States (39)  ·  China (23)  ·  Canada (19)  ·  United Kingdom (9)  ·  Australia (5)  ·  Belgium (5)  ·  Netherlands (5)  ·  Spain (5)  ·  Brazil (4)  ·  Egypt (4)  ·  France (4)  ·  Italy (4)  ·  Israel (3)  ·  Russia (3)  ·  South Korea (3)

Top investigators

Alfonso Gomez-Iturriaga, MD, PhD (2)  ·  Allan J Pantuck, MD (2)  ·  Arie S Belldegrun, MD (2)  ·  Basil Kasimis, MD (2)  ·  Donald B Fuller, M.D. (2)  ·  Laurence Klotz, MD (2)  ·  Mark Emberton, MD, FRCS, MBBS (2)  ·  Michiel Sedelaar, MD, PhD (2)  ·  Yonghong Li, M.D. (2)  ·  Abolfazl Razzaghdoust (1)  ·  Ahmed Shokeir, PhD (1)  ·  Alfonso Gomez-Iturriaga, MD (1)  ·  Anders Widmark, Prof MD (1)

Results publications

PMID 12126818, PMID 15042609, PMID 15143084, PMID 15470213, PMID 15470214, PMID 16985954, PMID 17587390, PMID 18930581, PMID 19091394, PMID 19286225, PMID 19308068, PMID 19359544, PMID 19399748, PMID 19996060, PMID 21470407, PMID 22056152, PMID 22500211, PMID 22614062, PMID 22866066, PMID 22894553, PMID 22932804, PMID 23063623, PMID 23619389, PMID 24290503, PMID 24321502, PMID 24412228, PMID 24464861, PMID 24472709, PMID 24821581, PMID 25104109, PMID 25217422, PMID 25566502, PMID 25682339, PMID 25687533, PMID 25819287, PMID 25888263, PMID 25937426, PMID 26215782, PMID 26309896, PMID 27150293, PMID 27296781, PMID 27836248, PMID 28498618, PMID 29153462, PMID 29606109, PMID 30528653, PMID 30545809, PMID 32356465, PMID 33102224, PMID 33203399

NIH funding

2016 (3), 2017 (2), 2008 (1), 2015 (1), 2019 (1), P30CA060553 (1), P30CA093373 (1)